StemExpress offers both COVID-19 molecular and serology (antibody) testing at its CLIA-certified laboratory locations.
StemExpress is one of the State of California's approved testing sites. The company has been working directly with the California Testing Task Force to offer testing to the general public and to specifically help skilled nursing facilities manage COVID-19 testing.
The nursing centers will use their licensed staff to collect specimens and send them to StemExpress' high complexity CLIA laboratory for testing.
Alternatively, StemExpress provides an option for comprehensive service including deploying medical staff on-site to complete specimen collection.
A recent analysis by the Texas-based Foundation for Research on Equal Opportunity found that 42% of all COVID-19 deaths in the US have occurred in long-term care facilities, such as nursing homes or assisted-living facilities.
StemExpress' multiple locations and specimen collection options will aid these vulnerable facilities to provide fast and high quality COVID-19 testing to their employees and residents.
StemExpress has the capacity to run more than 10,000 PCR tests and 8,000 ELISA based serology tests daily ensuring critical facilities can receive results quickly.
PCR testing will provide a positive or negative result for the virus. Serology testing will provide information as to whether the patient has been exposed to the virus previously and has built an antibody immune response.
All COVID-19 tests conducted at StemExpress have been authorized for use by the FDA under Emergency Use Authorization.
StemExpress is a life science biotechnology company that serves scientists across the globe by providing primary cells critical for disease research and now performs COVID-19 testing.
The company's goal is to advance science with a deep commitment to acceleration because the work done at StemExpress saves and improves lives.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT